Search details
1.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast Cancer Res Treat
; 204(2): 237-248, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38112922
2.
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Biosci Trends
; 14(1): 48-55, 2020 Mar 16.
Article
in English
| MEDLINE | ID: mdl-32023563
Results
1 -
2
de 2
1
Next >
>>